Canaccord Adjusts Well Health Estimates, Leaves Ratings Unchanged

This morning, Canaccord Genuity raised their estimates on WELL Health Technologies (TSX: WELL) off the back of a strong third quarter but kept their 12-month price target and rating at C$8.50 and a speculative buy.

Doug Taylor, Canaccord’s analyst, comments, “We remain positive on WELL Health following Q3 results, which featured a better revenue build than we previously forecasted.” WELL Health reported $12.2 million in revenue compared to the Street estimate of $11 million. They also reported an EBITDA loss of $0.2 million versus the estimate of $0.4 million. Taylor says that this beat was driven by sequential growth in clinic and virtual visits.

Taylor adds, “Increasing our forecasts for better growth and recent M&A.” He cites management saying that their current run rate is $68 million, which includes recent acquisitions. He says, “which we see as providing good support for our current model and expectations.”

Granada Gold Mine Inc. — sponsored Sponsored · Granada Gold Mine Inc.

Canaccord increased its revenue estimates for the fourth quarter, 2020, and 2021, along with the estimates for adjusted EBITDA, and EPS. He comments, “We have also increased near-term opex to reflect expectations of additional advertising and promotional activity along with the absorption of INSIG’s operations.”

The firm is now forecasting revenue to be $14.6 million for the fourth quarter, $47.6 million for 2020, and $74.8 million 2021.

Taylor comments on the estimate changes by stating, “Near-term outlook boosted by organic growth and M&A activity.” Clinical volumes continue to grow, and telehealth is holding over their third-quarter levels. The company has also indicated that they could expand their existing clinical business by +40% without hitting any capacity constraints.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

One Response

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Microsoft: Mixed Feelings Following Third Quarter Earnings

Microsoft (NASDAQ: MSFT) opened lower following the release of its financial results earlier this week,...

Saturday, May 1, 2021, 12:57:00 PM

IAMGOLD: Analysts Lower Price Targets Following Q4 Prelim Results

Yesterday, IAMGOLD Corp (TSX: IMG) released their preliminary operating results for the fourth quarter and...

Thursday, January 21, 2021, 11:53:00 AM

Curaleaf Sees Consensus Estimates Stay Flat After Q1 Results

Curaleaf Holdings (CSE: CURA) reported its first-quarter results on May 10th, beating the consensus estimates...

Saturday, May 15, 2021, 04:24:00 PM

Canaccord Slightly Lowers SSR Mining’s Price Target Off Back Of 2022 Guidance

Recently, SSR Mining Inc. (TSX: SSRM) announced full-year 2021 production results, a three-year outlook, and...

Friday, February 11, 2022, 05:10:00 PM

Argonaut Gold: BMO Lowers Target To $3.25 After Facilitating Bought Deal Financing

On March 3rd, Argonaut Gold (TSX: AR) announced that it has closed a bought deal....

Sunday, March 13, 2022, 03:10:00 PM